Pfizer downgraded to Neutral from Buy at UBS - InvestingChannel

Pfizer downgraded to Neutral from Buy at UBS

UBS analyst Colin Bristow downgraded Pfizer to Neutral from Buy with a price target of $47, down from $55. COVID estimates for Pfizer still need to come down and the company’s pipeline upside is minimal in the near- to mid-term, the analyst tells investors in a research note.

Related posts

Advisors in Focus- January 6, 2021

Gavin Maguire

Advisors in Focus- February 15, 2021

Gavin Maguire

Advisors in Focus- February 22, 2021

Gavin Maguire

Advisors in Focus- February 28, 2021

Gavin Maguire

Advisors in Focus- March 18, 2021

Gavin Maguire

Advisors in Focus- March 21, 2021

Gavin Maguire